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Division of Gastroenterology, Department of Internal Medicine-Gastroenterology, University of Michigan, Ann Arbor, MI, USA
The host immune response to gastrointestinal (GI) infections, hypersensitivity reactions, 
or GI cancers comprises numerous pathways that elicit responses on different host cells. 
Some of these include (1) the stimulation of mast cells via their IgE receptor, (2) the pro-
duction of antibodies leading to antibody-mediated cytotoxic T/natural killer cell killing, (3) 
the activation of the complement pathway, and (4) the activation of the adaptive immune 
response via antigen-presenting cell, T cell, and B cell interactions. Within the plethora 
of these different responses, several host immune cells represent major key players 
such as those of myeloid lineage (including neutrophils, macrophages, myeloid-derived 
suppressor cells) or lymphoid lineage (including T and B cells). In this review, we focus 
on newly identified metabolites and metabolite receptors that are expressed by either 
myeloid or lymphoid lineages. Irrespective of their source, these metabolites can in certain 
instances elicit responses on a wide range of cell types. The myeloid-expressed metabolic 
enzymes and receptors which we will discuss in this review include arginase 2 (Arg2), 
indoleamine-2,3-dioxygenase 1 (IDO1), hydroxycarboxylic acid receptor 2 (Hcar2; also 
called GPR109A), and immunoresponsive gene 1 (Irg1). We will also review the role of 
the lymphoid-expressed metabolite receptor that binds to the sphingosine-1-phosphate 
(S1P) sphingolipid. Moreover, we will describe the synthesis and metabolism of retinoic 
acid, and its effect on T cell activation. The review will then discuss the function of these 
metabolites in the context of GI disease. The review provides evidence that metabolic 
pathways operate in a disease- and context-dependent manner—either independently 
or concomitantly—in the GI tract. Therefore, an integrated approach and combinatorial 
analyses are necessary to devise new therapeutic strategies that can synergistically 
improve prognoses.
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iNTRODUCTiON
The host immune response—during infections or carcinogenesis—comprises a plethora of stimula-
tory and inhibitory signals. These manifest in numerous cellular activities, which are underscored 
by extensively complicated, variegated, and overlapping molecular and cellular interactions. 
Metabolites—such as those generated by amino acid breakdown—comprise a subset of the above-
mentioned signals, which can regulate the outcome of host immunopathology in a context-dependent 
(i.e., disease-specific) manner.
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In this article, we will first briefly review several components 
of the host immune response in the gastrointestinal (GI) tract. 
Then, we will outline specific contexts in which metabolites 
and/or metabolite receptors influence these components of host 
immunity. We will describe the source of these metabolites, 
and the critical steps that can control the immunopathological 
outcome. By contrast, we will also discuss the manner in which 
failed approaches can arise in targeting these pathways. Due to 
our inability to review the entire metabolome, we will focus on 
eight specific metabolites and their receptors, which epitomize 
distinct and variegated responses. The review will focus on 
the roles of arginase 2 (Arg2), indoleamine-2,3-dioxygenase 1 
(IDO1), hydroxycarboxylic acid receptor 2 (Hcar2; also called 
GPR109A), immunoresponsive gene 1 (Irg1), sphingosine-
1-phosphate (S1P), and all-trans-retinoic acid (atRA).
HOST iMMUNiTY iN THe Gi TRACT
The host immune response comprises the initiation of several 
reactions that are carried out by a subset of white blood cells 
(WBCs), or leukocytes. These WBCs are divided into two line-
ages, myeloid and lymphoid, which arise from a hematopoietic 
stem cell origin (1). The hematopoietic stem cell gives rise to 
common lymphoid progenitors (CLPs) and common myeloid 
progenitors (CMPs) (1). The lymphoid lineage arises from the 
CLP and comprises B cells (and mature plasma cells), T cells, and 
natural killer (NK) cells (2, 3). The myeloid lineage arises from the 
CMP and comprises monocytes, macrophages, dendritic cells, 
neutrophils, eosinophils, basophils, mast cells, megakaryocytes, 
and erythrocytes (2, 3).
After a foreign antigen is detected by a subset of myeloid 
cells (4) or B cells (5), these cells can either elicit an autonomous 
thymus-independent response (6), or otherwise interact with 
T cells to elicit an acquired T cell-dependent response (6). The 
cells that detect the antigen are known as antigen-presenting cells 
(APCs) because they are able to present antigen to T cells (7). As 
mentioned above, APCs are usually myeloid (mainly dendritic 
cells) (4), but can also be of the B cell lineage (5). These cells 
detect foreign antigen in the mucosa of the affected GI tissue (8). 
However, they can also detect antigen in tissue-draining lymph 
nodes if the foreign antigen was in circulation and reached the 
lymph nodes via afferent lymphatic vessels (9–11). Once APCs 
detect foreign antigen they can elicit an autonomous T cell-
independent response; for example dendritic cells can produce 
cytokines (12) while B cells can produce antibody in a T cell-
independent manner (13). Alternatively, APCs can travel to the 
lymph nodes via afferent lymphatic ducts (12, 14) and interact 
with T cell receptors on T cells via their major histocompatibility 
II (MHC-II) molecules, and as a result elicit a T cell-dependent 
response (15, 16). The APC:T cell interaction usually occurs in 
the paracortex of tissue-draining lymph nodes (16), although 
this interaction can also occur in tertiary lymphoid organs of the 
affected tissue in situ (17–19). Antigen presentation by dendritic 
cells to T cells sequentially leads to T cell–B cell interactions, thus 
triggering B cell maturation and antibody production (20, 21).
Numerous variegated—but coincidental—cellular activities 
regulate the outcome of host immunity in the GI tract, but some 
of the pathways are epitomized by the activities observed during 
hypersensitivity reactions (22–24). In type I hypersensitivity, a 
target antigen leads to the stimulation of mast cells via their IgE 
receptors leading to degranulation (22–24). In type II hypersen-
sitivity, antibodies bind to target cells leading to direct cell to cell 
killing by NK or CD8+ T cells (22–24). Type III hypersensitivity 
comprises the binding of complement to the target antigen lead-
ing to chemotaxis and infiltration of neutrophils (22–24). Type 
IV hypersensitivity is mediated by cytokine release from helper 
T cells that stimulate macrophage or killer T cell activity against 
target cells (22–24). Overall, these pathways do not only operate 
in hypersensitivity or autoimmune reactions, but also in regular 
pathogenesis (25) in response to infection or carcinogenesis. 
For example, cytokines that exacerbate host immunopathology 
are induced in the cecum during Clostridium difficile infection 
(26) and in the stomach during chronic Helicobacter felis-
induced gastritis (27). Both of these pathological phenomena 
are reminiscent of type IV autoimmunity (22–24). In addition, 
autoantibody production (28–38) and complement activation 
(39, 40) are detected during Helicobacter pylori gastritis, which 
are also reminiscent of type II and type III autoimmunity, 
respectively (22–24).
In summary, this paragraph outlines some of the complex-
ity of host immunity and its coincidental activities of targeting 
pathogen versus host. The complexity of these pathways renders 
it unattainable to review all these processes. Hence, we will focus 
our review on two processes for which metabolite involvement 
has been characterized to a certain extent: (1) the role of metabo-
lites in regulating myeloid cell function (namely the roles of Arg2, 
IDO1, Hcar2, and Irg1), and (2) the role of metabolites that exert 
a direct effect on CD8+ T cell migration and memory (namely 
S1P), or on CD8+ T cell activation via epithelial cell mediation 
(retinoic acid).
Arg2 iN SUPPReSSiNG MACROPHAGe 
CYTOTOXiCiTY AND MYeLOiD-DeRiveD 
SUPPReSSOR CeLL (MDSC) FUNCTiON
Arginase 2 is an enzyme for which two previously defined 
mechanisms have been described: (1) Arg2 reduces macrophage 
cytotoxic activity (41) by depleting l-arginine availability for the 
production of nitric oxide (NO) by nitric oxide synthase (NOS) 
(42); and (2) Arg2 in MDSCs inhibits T cell immunity by deplet-
ing l-arginine availability for T cells in the inflamed microenvi-
ronment (43) (Figure 1A). l-arginine is a non-essential amino 
acid that is sufficiently produced by the human body, but becomes 
essential in disease contexts that upregulate Arg2 (44). Therefore, 
the use of l-arginine as a dietary supplement for treating disease 
is arguable since the pathway is regulated at the level of l-arginine 
breakdown. However, the metabolic enzyme Arg2 presents an 
attractive therapeutic target for modulating T cell immunity (45). 
In order to review the role of Arg2, it is important to outline the 
nature and function of MDSCs in tumor biology and autoim-
mune pathology.
Myeloid-derived suppressor cells are a myeloid population 
(that can be regulated by intrinsic Arg2 activity), which exerts 
FiGURe 1 | Diagrammatical modeling of exemplary metabolic pathways that regulate host immunity. (A) Arginase 2 (Arg2) functions by regulating two 
pathways: (i) depletion of l-arginine required for NO synthesis contributing to macrophage cytotoxic activity against pathogens; and (ii) depletion of l-arginine 
required for T cell immunity. (B) IDO1 has been traditionally described to suppress T cell immunity by depleting tryptophan. Moreover, IDO1 generates kynurenine 
that stimulates Tregs. However, new alternative mechanisms for IDO1 have recently been described: (i) IDO1 suppresses (potentially via kynurenine) IFN-γ-producing 
cecal neutrophils during Clostridium difficile colitis; and (ii) IDO1-produced metabolites (such as kynurenine) stimulate the β-catenin pathway and tumor epithelial cell 
proliferation in colorectal cancer. (C) GPR109A (also known as hydroxycarboxylic acid receptor 2) is the niacin/butyrate receptor which exhibits two previously 
described functions: (i) in myeloid cells GPR109A suppresses IL-6 and T cell immunity, while promoting IL-10 production and Treg differentiation; and (ii) in epithelial 
cells GPR109A suppresses IL-18 production. (D) Irg1 is an enzyme that regulates the tricarboxylic acid (TCA) (citric acid) cycle in the mitochondria of myeloid cells. 
Irg1 regulates two functions: (i) Irg1 generates itaconate, which exhibits antimicrobial activities by inhibiting the bacterial enzyme isocitrate lyase; and (ii) Irg1 inhibits 
succinate dehydrogenase (Sdh), which leads to an increase in succinate levels. Increased succinate suppresses pro-inflammatory cytokines (IL-1β, IL-12) and 
hypoxia-inducible factor 1 alpha (HIF-1α). (e) S1P provides a high gradient in efferent lymphatic vessels of the lymph node, which leads to the egress of memory T 
cells expressing high levels of the S1pr1 receptor. In non-lymphoid tissue, low levels of S1pr1 are necessary for sustaining tissue-resident memory T (TRM) cells by 
continuously preventing egress out of the tissue via lymphatic ducts.
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immunosuppressive activities against T cells (46). The regulation 
of effector T cell function by MDSCs is critical in pathological 
situations (47, 48). The reason T cells are important is because, 
for example in cancer, CD8+ cytotoxic T cells exhibit antitumor 
activity by killing tumor cells (49). In viral infections, CD8+ 
T cells confer protection by eliminating virus-infected cells 
(49). However, the effect of MDSC on T cell function is also 
complicated by the fact that T cells exhibit variable phenotypes 
depending on two intertwined phenomena: (1) homing receptor 
expression, and (2) differentiation into specific T cell memory 
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subtypes (50). The latter point will not be discussed here, but 
will be discussed in the last section of this article regarding S1P. 
Nevertheless, MDSCs are believed to play an unfavorable role in 
cancer and viral infections by suppressing T cell immunity (46). 
Hence, this suppressive activity of MDSCs against T cells is partly 
mediated by Arg2, which unravels an attractive therapeutic target 
against cancer (46). However, in vivo pathological situations warn 
of arguable outcomes for this strategy as will be described in the 
following paragraph.
The reason why the usefulness of Arg2 inhibitors against 
GI cancer is arguable is epitomized by a study in which Arg2 
deficiency exacerbated gastric immunopathology during 
chronic gastritis (51, 52). The authors showed that this effect 
was not mediated by NOS (52). Even though the authors did 
not investigate the effect of reduced MDSC function on CD8+ T 
cell responses in this model, they did report a dramatic increase 
in tissue IFN-γ levels—a cytokine that is mainly produced by 
CD8+ T cells and NK cells (51, 52). Hence, if Arg2−/− leads to 
reduced MDSC function and increased CD8+ T cell response—as 
reported in the literature—the worsened immunopathology 
in Arg2−/− would suggest that CD8+ T cells are involved in an 
autoimmune etiology in the stomach. In this scenario, the use 
of Arg2 inhibitors to treat cancers becomes arguable since the 
inflamed normal tissue—adjacent to the tumor—might develop 
worsened immunopathology when Arg2 is inhibited. Therefore, 
one has to consider the unfavorable pathological outcome of Arg2 
suppression, which might arise due to heightened inflammation 
in normal adjacent tissue to the tumor, which can exacerbate the 
development of preneoplastic metaplastic lesions.
AN UNUSUAL ROLe FOR iDO1 iN 
SUPPReSSiNG CeCAL iFN-γ- 
PRODUCiNG NeUTROPHiLS
IDO1 is a tryptophan-catabolizing enzyme that suppresses T cell 
immunity (53), but has recently been shown to play major alter-
native roles (other than T cell regulation) in the GI tract (26, 54) 
(Figure 1B). The role of IDO1 in regulating T cell immunity was 
first described in the prevention of allogeneic fetal rejection (53). 
In the latter study, IDO1 was proposed to deplete tryptophan 
pools for T cells by catabolizing tryptophan into kynurenine (53). 
In correlation with this finding, IDO1 inhibitor increased CD8+ 
T cells and reduced tumor growth in a transgenic mouse model 
of cecal gastrointestinal stromal tumors, which was reversed by 
CD8+ T cell depletion (55). Furthermore, IDO1 is expressed by 
MDSCs and regulates the immunosuppressive function of these 
cells against T cells (56). Alternatively, the mechanism of anti-T 
cell immunity of IDO1 can also be attributed to plasmocytoid 
dendritic cell expression of IDO1 in tumor-draining lymph 
nodes (57). In contrast to the latter observations, our recent 
finding demonstrates that IDO1 plays other distinct functions in 
non-tumor inflammatory environments that do not employ T cell 
immunity as a major component (26). Moreover, another recent 
study also showed that IDO1 plays a critical role in regulating 
epithelial cell function, which affects the outcome of colorectal 
cancer development in mouse models (54). The latter two 
observations indicate that the functions of IDO1 are not limited 
to regulating T cell immunity, but are subject to variability based 
on pathogenic context. These two studies will be reviewed in the 
following two paragraphs.
In our recent study, IDO1 suppressed IFN-γ-producing 
neutrophils in C. difficile colitis, but had no apparent effect on 
cecal CD4+ T cell number (26). It is important to note that C. 
difficile colitis is an acute neutrophilic disease (58), in which T 
cells do not affect immunopathology or survival in a significant 
manner (59). The latter observation was supported by the use 
of Rag1−/− mice, which succumbed to similar immunopathol-
ogy relative to wild-type mice during C. difficile infection (59). 
Our observation that IDO1 deficiency led to increased cecal 
neutrophils (26) correlates with a recent finding that the IDO1 
metabolite, kynurenine, suppresses neutrophil chemotaxis 
potentially via the aryl hydrocarbon receptor (60). The other 
surprising finding in our study was that cecal neutrophils—regu-
lated by IDO1—were the major source (>90%) of IFN-γ (26). 
The latter observation also correlates with neutrophils being the 
major source of IFN-γ during Salmonella enterica Typhimurium-
induced colitis (61). Therefore, the breakdown of the amino acid 
tryptophan into kynurenine in this context inhibits chemotaxis 
of IFN-γ-producing neutrophils during infectious colitis of the 
lower bowel. These findings unravel a novel role for IDO1 during 
acute infections of the GI tract, which warn of unfavorable side 
effects for IDO1 inhibitors. This is of special concern since cancer 
patients are more likely to succumb to C. difficile infections (62). 
Moreover, the findings also propose that IDO1 might potentially 
play alternative functions that regulate myeloid cells (e.g., neu-
trophils or MDSCs) in other contexts, such as tumor context. 
In support of the latter proposition, a recent paper showed that 
MDSCs were increased in IDO1-overexpressing B16 melanoma 
tumor models (63).
In addition to our observed effect of IDO1 on neutrophils, 
another study demonstrated a novel function of IDO1 in regulat-
ing epithelial cancer cell proliferation. The authors showed that 
IDO1 deficiency led to reduced tumor burden in the azoxym-
ethane (AOM) and dextran sodium sulfate (DSS) model, which 
was mediated by a T cell-independent mechanism (54). The 
finding was similarly replicated in Rag1−/− mice that lack T and 
B lymphocytes, thus corroborating that T cells were not involved 
(54). The authors proposed that IDO1 influenced tumor devel-
opment by regulating epithelial cell proliferation via β-catenin 
(54). Therefore, we conclude—based on the data from the last 
two paragraphs—that IDO1 plays additional T cell-independent 
roles, which are variable according to disease context. Hence, 
these pathways should be taken into consideration during the 
therapeutic design for IDO1 inhibitors.
THe NiACiN/BUTYRATe ReCePTOR, 
GPR109A, SUPPReSSeS iNFLAMMATORY 
ReSPONSeS iN MYeLOiD CeLLS AND 
THe COLONiC ePiTHeLiUM
GPR109A (also known as the Hcar2) is a G-protein-coupled 
receptor (GPCR) that binds niacin (vitamin B3) and butyrate 
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(64). Its first ligand, niacin, can be consumed from meats (e.g., 
fish, chicken, liver, turkey, and pork), vegetables (e.g., peas and 
mushrooms), cereal, and peanuts (65). Interestingly, some of the 
dietary requirement for niacin is provided by the production of 
nicotinic acid from the tryptophan/kynurenine pathway (66) 
mediated by IDO1. Its second ligand, butyrate, is produced by the 
gut microbiota via the fermentation of dietary fiber from plant 
products (67, 68).
Given the complexity of GPCR pathways (69), GPR109A 
plays variegated functions in different contexts. For example, 
GPR109A mediates the antidyslipidemic effect of nicotinic 
acid in decreasing low-density lipoprotein and triglycerides, 
and increasing high-density lipoprotein levels (70). This led to 
the use of nicotinic acid as an antihyperlipidemic agent (70), 
although its use is limited by the unfavorable side effect of 
cutaneous vasodilation, leading to skin flushing (70). This effect 
on the skin arises because, in addition to GPR109A expression 
by adipocytes (71), the receptor is also expressed by cutaneous 
immune cells (72) and epidermal Langerhan cells (73). Overall, 
GPR109A is generally highly expressed by myeloid cells such 
as neutrophils (74, 75), macrophages, monocytes, and den-
dritic cells (76, 77). It is also expressed by intestinal epithelial 
cells (78). Hence, it is not surprising for GPR109A to play an 
important role in regulating intestinal immunopathology and 
carcinogenesis.
The role of GPR109A has recently been described in suppress-
ing colonic inflammation and cancer (77) (Figure  1C). In the 
latter study, the authors described GPR109A-deficient intestinal 
myeloid cells to express lower levels of IL-10 and exhibit a 
deficiency in their ability to stimulate Treg differentiation (77). 
The authors also showed that GPR109A−/− colonic epithelial 
cells were unable to produce IL-18 (77). Finally, the authors 
showed that GPR109A deficiency exacerbated tumor develop-
ment in the AOM/DSS model (77). Bone marrow transplant 
experiments revealed that the antitumor GPR109A effect was 
mediated by both the epithelial and immune compartments 
(77). Interestingly, treatment with niacin suppressed colonic 
inflammation and carcinogenesis in this model (77). In addition, 
similar findings were observed in another study that utilized 
high- versus low-fiber diets and GPR109A-deficient mice (79). 
In conclusion, GPR109A is a metabolic receptor for niacin and 
butyrate for which the therapeutic value, in GI inflammation and 
carcinogenesis, should be evaluated. Since GPR109A is highly 
expressed in myeloid cells, it would be additionally interesting 
to evaluate the role of this receptor in MDSCs. This is especially 
important given the MDSC role in suppressing CD8+ T cell 
antitumor immunity.
THe iTACONiC ACiD-PRODUCiNG 
eNZYMe, irg1, iN ReGULATiNG 
SUCCiNATe LeveLS AND THe 
iNFLAMMATORY ReSPONSe iN 
MACROPHAGeS
Immunoresponsive gene 1 (Irg1) is a mitochondria-associated 
metabolic enzyme that exhibits (1) an anti-inflammatory 
activity in host myeloid cells (80), and (2) an antimicrobial activ-
ity against pathogens (81, 82). Irg1 functions by decarboxylating 
cis-aconitic acid to produce itaconate, as part of the tricarboxylic 
acid (TCA) cycle (also known as the citric acid cycle) (Figure 1D) 
(81). The production of itaconate can generate an antimicrobial 
response by inhibiting the bacterial enzyme isocitrate lyase (81, 
82). Moreover, in host myeloid cells, Irg1 functions by inhibiting 
succinate dehydrogenase (Sdh) (83–85), an enzyme that oxidizes 
succinic acid to fumaric acid within the TCA cycle. The inhibi-
tion of Sdh by Irg1-mediated itaconate sustains an accumulation 
of succinate during LPS stimulation and a decrease in the levels 
of fumarate and malate (80) (Figure 1D). Moreover, Irg1 sup-
presses inflammatory cytokine expression in myeloid cells such 
as IL-1β, IL-12, IL-6, IL-18, and the hypoxia-inducible factor 1 
alpha (HIF-1α) (80). Hence, the mechanism of Irg1 and itaconate 
appears to be mediated by succinate inhibition, the latter of which 
can regulate major inflammatory pathways [such as HIF-1α (80)] 
in myeloid cells (86). In comparison to the previously described 
function of Irg1 against bacterial infections (81, 82), a recent 
study showed that the treatment with dimethyl itaconate did not 
affect the number of intracellular bacteria following Salmonella 
typhimurium infection of bone marrow-derived macrophages 
(80). Therefore, despite the established effect of Irg1 in myeloid 
cell responses (80), the antimicrobial effect of Irg1 remains 
debatable.
Given the above-described functions of Irg1, this molecule 
now represents an attractive target to investigate in GI diseases 
and cancer. To date, there have been no mechanistic reports on 
the function of Irg1 in the GI tract. However, two studies reported 
the induction of Irg1 in response to Salmonella infection in the 
chicken cecum. Hence, Irg1 represents a ripe topic for investiga-
tion in GI diseases and cancer (87–89).
THe SPHiNGOSiNe-1-PHOSPHATe 
SPHiNGOLiPiD iN ReGULATiNG eGReSS 
OF MeMORY T CeLLS
Sphingosine-1-phosphate (S1P) is a signaling sphingolipid that 
regulates lymphocyte egress from secondary lymphoid organs 
(such as lymph nodes) (90) or non-lymphoid tissue (91, 92) 
(Figure  1E). S1P levels are high in efferent lymphatic ducts 
(higher than interstitial fluid of secondary lymphoid organs) 
(93), which attract lymphocytes that express high levels of 
sphingosine-1-phosphate receptor 1 (S1pr1) to egress out of the 
organs into the lymphatic ducts (93). This leads to recirculation 
of these lymphocytes via the lymphatic ducts and/or blood 
vessels (94). Once these lymphocytes egress, they downregulate 
their S1pr1 expression (95). Moreover, in the case of lymphocytes 
that constantly reside in non-lymphoid organs, such as tissue-
resident memory T (TRM) cells, the consistent low expression of 
S1pr1 is necessary to sustain these cells within the organ without 
recirculation (92). In discussing the role of S1P, it is important 
to consider its dietary sources and the effect of its intake on GI 
disease outcome.
S1P is derived from dietary sphingolipids (96) that 
can impact the outcome of GI disease and cancer (97). 
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Sphingosine-1-phosphate (S1P) lyase is an enzyme that 
degrades S1P in enterocytes, and its intestinal deletion leads to 
S1P accumulation in the colon, and an increase in T cells and 
colon carcinogenesis (97). The dietary source of S1P is variable 
and high levels can be consumed from dairy products, meats, 
and eggs, whereas vegetables and fruits contain lower levels 
(98). However, it is unclear whether the amount of dietary 
intake of S1P is critical. This is because lymphocyte differentia-
tion and homing can be regulated at the level of expression of 
the S1P receptor, S1pr1, in lymphocytes—as will be reviewed 
in the following paragraph.
S1pr1 regulates T cell homing, which directly impacts T 
cell memory differentiation (92, 99–101). There are three types 
of memory T cells, which include (i) central memory T cells 
(TCM), (ii) effector memory T cells (TEM), and (iii) TRM. TCM cells 
patrol lymph nodes and the white pulp of the spleen, and they 
express lymph node homing receptors (99–101). TEM circulate 
between the blood and non-lymphoid tissue, but do not express 
homing receptors (99–101). TRM are resident in the tissue and 
do not recirculate into the blood or secondary lymphoid organs 
(99–101). The homing of these cells is directly intertwined with 
their function and differentiation (99–101). As different types of 
memory T cells can exhibit different functions (99–101), the role 
of S1P and S1pr1 becomes critical in regulating disease outcome. 
This is especially important in regulating CD8+ T cell memory 
phenotypes to modulate their cytotoxic activities against tumors, 
or pro-inflammatory activities in autoimmune diseases. In sup-
port of the latter point, current drugs against S1pr1 in colon 
cancer have been considered (102) and are currently undergoing 
clinical trials for inflammatory bowel diseases and colorectal 
cancers.
THe viTAMiN A MeTABOLiTe, atRA, iN 
ReGULATiNG ePiTHeLiAL MHC-i 
eXPReSSiON AND CD8+ T CeLL 
ACTivATiON
All-trans-retinoic acid is a vitamin A metabolite that induces 
epithelial MHC-I expression in mouse models of colon carcino-
genesis, therefore, triggering CD8+ T cell antitumor immunity 
(103). Vitamin A can occur in two basic forms, which are, 
respectively, obtained from two different dietary sources: (i) 
retinoids are supplied by animal food, whereas (ii) carotenoids 
are obtained from plant products (104). Retinyl palmitate con-
stitutes the major form of vitamin A from animal food, which is 
converted in the small intestine to retinol, then to retinaldehyde, 
and then to retinoic acid (104). The synthesis of retinoic acid in 
the small intestine is mediated by retinaldehyde dehydrogenase 
enzymes, such as Aldh1a1, Aldh1a2, and Aldh1a3 (105–107), 
which are expressed by both intestinal epithelial and immune 
cells (103). In contrast to animal food sources, plant products 
provide carotenoids (provitamin A), which can be broken 
down into beta-carotene and then retinol in the intestinal 
mucosa (106). In both scenarios, the metabolic enzymes that 
regulate the synthesis or breakdown of retinoic acid in the small 
intestine provide an important checkpoint that can determine 
the resulting abundance of intestinal retinoic acid. The recent 
study by Bhattacharya et  al. (103) demonstrated that in the 
AOM/DSS model, colon carcinogenesis led to downregulation 
of the atRA-synthesizing enzyme Aldh1a1. The downregula-
tion of this enzyme was observed in both the epithelial and 
immune cell compartments (103). This was accompanied by 
an upregulation of the atRA-catabolizing enzyme, Cyp26A1, 
in the epithelial compartment of the colon mucosa (103). The 
authors went on to show that atRA reduced tumor burden 
in the AOM/DSS model and that this was mediated by the 
stimulation of atRA for epithelial MHC-I expression. Overall, 
the authors showed that mucosal inflammation, triggered by 
the host microbiota during colitis-associated colorectal cancer, 
stimulated atRA metabolism to decrease its levels, leading to 
reduced MHC-I and CD8+ activation (103). It will additionally 
be insightful to determine the effect of retinoic acid on CD8+ T 
cell memory differentiation as will be discussed in the following 
paragraph.
Previous studies have shown that atRA inhibits TGF-β-
mediated Th17 differentiation and stimulates Treg differentiation 
(108–110). However, those studies also showed that atRA stimu-
lates gut homing receptor expression, of α4β7 integrin and CD103, 
on T cells (108, 109). Hence, given the role of TGF-β-mediated 
induction of α4β7 integrin and CD103 in TRM generation (111), 
it will be insightful to determine the mechanism in which atRA 
regulates TRM, TCM, and TEM differentiation. Such analyses will 
also unravel novel information about the distinct roles of these 
memory T cell subtypes in colon carcinogenesis.
CONCLUDiNG ReMARKS
This article presents a number of scenarios in which metabolites 
and their receptors regulate the outcome of GI disease and 
cancer (Figure  1). In considering these scenarios, it is impor-
tant to realize that several of these pathways can be triggered 
coincidentally within the same context of disease. Therefore, an 
integrated approach and combinatorial analyses are necessary to 
devise new therapeutic strategies that can synergistically improve 
prognoses. Theoretically, modulating these metabolic pathways 
to improve disease outcome should be feasible. However, what 
is not known are the “recipes” in which interrupting or alter-
ing these pathways would concomitantly lead to significantly 
improved outcomes.
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